Search

Displaying results 1501 - 1510 of 10000 in total
  1. Drug

    Bupropion

    go.drugbank.com/drugs/DB01156
    ApprovedInvestigational

    [A6399,A178810] Bupropion was originally classified as an "atypical" antidepressant because it does not exert the same effects as the classical antidepressants such as Monoamine Oxidase Inhibitors ( … More specifically, bupropion binds to the norepinephrine transporter (NET) and the dopamine transporter (DAT).

  2. Drug

    Dipyrithione

    go.drugbank.com/drugs/DB11327
    Approved

    Dipyrithione, a bactericidal and fungicidal pyrithione derivate, was formulated as Crimanex anti-dandruff shampoo, but is no longer available. … [L2615] Dandruff is a common scalp disease affecting >40% of the world's adult population, and may be caused by fungi such as _Malassezia globosa_ and _M. restricta_.[A32162]

  3. Drug

    Darvadstrocel

    go.drugbank.com/drugs/DB16581
    ApprovedInvestigationalWithdrawn

    [A244524] Darvadstrocel was first approved by the European Commission on March 23, 2018, under the brand name Alofisel. … It is indicated for the treatment of complex perianal fistulas in adult patients with non-active or mildly active luminal Crohn’s disease when fistulas have shown an inadequate response to at least one

  4. Drug

    Quercus stellata pollen

    go.drugbank.com/drugs/DB10888
    Approved

    Quercus stellata pollen is the pollen of the Quercus stellata plant. Quercus stellata pollen is mainly used in allergenic testing.

    Mixtures: 5-oak Mix, Blackjack/bur/post/red/white PollenCategories: Non-Standardized Pollen Allergenic Extract
  5. Drug

    Avacopan

    go.drugbank.com/drugs/DB15011
    ApprovedInvestigational

    [A240269, A240329, L38919] Avacopan was granted FDA approval on October 8, 2021, and is currently marketed under the name TAVNEOS by ChemoCentryx, Inc. … [L39850] Avacopan was approved by Health Canada on April 20, 2022.[L41650]

  6. Drug

    Lenalidomide

    go.drugbank.com/drugs/DB00480
    ApprovedInvestigational

    [A228708] Available as oral capsules, lenalidomide is approved by the FDA and EU for the treatment of multiple myeloma, myelodysplastic syndromes, mantle cell lymphoma, follicular lymphoma, and marginal

  7. Drug

    Macitentan

    go.drugbank.com/drugs/DB08932
    ApprovedInvestigational

    [L39105] It was subsequently approved by the FDA in March 2024.[L50622] … [L35890] It was first approved by the FDA in 2013. Macitentan differs from its predecessor [bosentan] in part due to its lower risk of hepatotoxicity.

  8. Target

    Tyrosine-protein phosphatase non-receptor type 1

    go.drugbank.com/bio_entities/BE0000623
    TargetHumans

    Tyrosine-protein phosphatase which acts as a regulator of endoplasmic reticulum unfolded protein response. Mediates dephosphorylation of EIF2AK3/PERK; inactivating the protein kinase activity of EIF2AK3/PERK. May play an important role i...

    Polypeptides: Tyrosine-protein phosphatase non-receptor type 1
  9. Target

    Non-selective voltage-gated ion channel VDAC3

    go.drugbank.com/bio_entities/BE0002470
    TargetHumans

    Non-selective voltage-gated ion channel that mediates the transport of anions and cations through the mitochondrion outer membrane and plasma membrane (PubMed:31935282).

    Polypeptides: Non-selective voltage-gated ion channel VDAC3
  10. Target

    Tyrosine-protein phosphatase non-receptor type 12

    go.drugbank.com/bio_entities/BE0009940
    TargetHumans

    Dephosphorylates a range of proteins, and thereby regulates cellular signaling cascades (PubMed:18559503). Dephosphorylates cellular tyrosine kinases, such as ERBB2 and PTK2B/PYK2, and thereby regulates signaling via ERBB2 and PTK2B/PYK2...

    Polypeptides: Tyrosine-protein phosphatase non-receptor type 12Function: non-membrane spanning protein tyrosine phosphatase activity